Intézmény

SKiN Health

Peterborough, KanadaHonlap

Más néven: The SKiN Centre for Dermatology

17futó vizsgálat
22lezárt vizsgálat
543publikáció (OpenAlex)

Futó vizsgálatok

Még nem toboroz
A Study to Assess the Safety and Effectiveness of COL-5671-PRO Capsules in Adults With Moderate-to-Severe Plaque Psoriasis
NCT07914231· 2. fázis· Coultreon Biopharma· Forrás
Fut, nem toboroz
A Study of Zasocitinib in Adults With Hidradenitis Suppurativa
NCT07244263· 2. fázis· Takeda· Forrás
Fut, nem toboroz
A Study of Zasocitinib in Adults With Nonsegmental Vitiligo
NCT07108283· 2. fázis· Takeda· Forrás
Toboroz
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
NCT07116967· 3. fázis· Bristol-Myers Squibb· Forrás
Toboroz
Study to Assess Change in Quality of Life of Risankizumab Treatment in Adult Participants With Moderate-to-Severe Plaque Psoriasis
NCT07039110· AbbVie· Forrás
Fut, nem toboroz
Study to Evaluate Tulisokibart for Hidradenitis Suppurativa (MK-7240-012)
NCT06956235· 2. fázis· Merck Sharp & Dohme LLC· Forrás
Toboroz
A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata
NCT06873945· 3. fázis· Pfizer· Forrás
Fut, nem toboroz
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
NCT06846541· 3. fázis· Alumis Inc· Forrás
Fut, nem toboroz
A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis
NCT06550076· 3. fázis· Takeda· Forrás
Fut, nem toboroz
A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2)
NCT06220604· 3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V1)
NCT06113445· 3. fázis· Incyte Corporation· Forrás
Fut, nem toboroz
A Study of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas (Scalp, Genital, and/or Palms of the Hands and the Soles of the Feet)
NCT06095102· 3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata
NCT06012240· 3. fázis· AbbVie· Forrás
Toboroz
A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata
NCT05723198· 3. fázis· Eli Lilly and Company· Forrás
Fut, nem toboroz
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy
NCT03675308· 3. fázis· AbbVie· Forrás
Fut, nem toboroz
A Longitudinal Observational Study of Patients Undergoing Therapy for IMISC
NCT03661866· Target PharmaSolutions, Inc.· Forrás
Fut, nem toboroz
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis
NCT03568318· 3. fázis· AbbVie· Forrás

Egyszerre toboroz

Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.

Pikkelysömör3 toboroz
Alopecia areata1 toboroz

Lezárt vizsgálatok

Lezárult
A Study Comparing Zasocitinib (TAK-279) With Deucravacitinib in Adults With Plaque Psoriasis
NCT06973291· 3. fázis· Takeda· Forrás
Lezárult
A Study to See How Well Lebrikizumab Works in Adults and Adolescents With Moderate Atopic Dermatitis (Eczema) and High Itch Burden
NCT07006792· 4. fázis· Eli Lilly and Company· Forrás
Lezárult
A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001
NCT06588738· 3. fázis· Alumis Inc· Forrás
Leállították
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VYN201 Gel in Subjects With Non-segmental Vitiligo.
NCT06493578· 2. fázis· Vyne Therapeutics Inc.· Forrás
Lezárult
A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis
NCT06238817· 3. fázis· Incyte Corporation· Forrás
Lezárult
An Observational Study to Validate the Cumulative Life Course Impairment (CLCI) Instrument (DermCLCI-p) in Adult Participants With Moderate to Severe Chronic Plaque Psoriasis (PsO)
NCT05959070· AbbVie· Forrás
Lezárult
A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period
NCT06108544· 3. fázis· Takeda· Forrás
Lezárult
A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of IMG-007 in Adult Alopecia Areata Participants
NCT06060977· 1/2. fázis· Inmagene LLC· Forrás
Lezárult
A Study to Assess Treat-to-Target and Dosing Flexibility of Oral Upadacitinib Tablets in Adult Participants With Moderate to Severe Atopic Dermatitis
NCT05507580· 4. fázis· AbbVie· Forrás
Lezárult
A Study to Assess the Safety and Efficacy of Ruxolitinib Cream in Participants With Genital Vitiligo
NCT05750823· 2. fázis· Incyte Corporation· Forrás
Lezárult
A Study Assessing Rocatinlimab in Combination With Topical Corticosteroid and/or Topical Calcineurin Inhibitors in Adult Participants With Moderate-to-severe Atopic Dermatitis (AD)
NCT05724199· 3. fázis· Amgen· Forrás
Lezárult
A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)
NCT05633355· 3. fázis· Amgen· Forrás
Lezárult
A Study Assessing Rocatinlimab (AMG 451) Monotherapy in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Horizon)
NCT05651711· 3. fázis· Amgen· Forrás
Lezárult
Study to Evaluate of the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa
NCT05635838· 2. fázis· Incyte Corporation· Forrás
Lezárult
A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis
NCT05601882· 3. fázis· AbbVie· Forrás
Lezárult
An Observational Study of Upadacitinib to Assess Change in Disease Activity in Canadian Adult Participants With Moderate-to-Severe Atopic Dermatitis Who Are Inadequate Responders To or Discontinuing Dupilumab
NCT05394792· AbbVie· Forrás
Lezárult
Study of DAXDILIMAB for the Treatment of Moderate-to-Severe Alopecia Areata
NCT05368103· 2. fázis· Amgen· Forrás
Leállították
PLACEBO-CONTROLLED SAFETY STUDY OF RITLECITINIB (PF-06651600) IN ADULTS WITH ALOPECIA AREATA
NCT04517864· 2. fázis· Pfizer· Forrás
Lezárult
Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin)
NCT04392154· 3. fázis· Eli Lilly and Company· Forrás
Lezárult
Long-Term PF-06651600 for the Treatment of Alopecia Areata
NCT04006457· 3. fázis· Pfizer· Forrás
Lezárult
Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis
NCT03422822· 3. fázis· Pfizer· Forrás
Lezárult
A Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis ( LIMMITLESS )
NCT03047395· 3. fázis· AbbVie· Forrás

Regiszterbeli névváltozatok (15)

A vizsgálati regiszterek ezeken a neveken tartják nyilván az intézményt. Minden sor egy regiszterbejegyzés: a címe és az alatta nyilvántartott vizsgálatok.

SKiN Centre for Dermatology
Peterborough, Ontario K9J 5K2
21 vizsgálat
SKiN Health
Cobourg, Ontario K9A 0Z4
4 vizsgálat
Skin Health
Peterborough, Ontario K9J 5K2
2 vizsgálat
- NCT06113445A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V1)
- NCT04392154Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin)
SKiN Health
Coburg, Ontario K9A 0Z4
2 vizsgálat
- NCT06846541Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
- NCT05724199A Study Assessing Rocatinlimab in Combination With Topical Corticosteroid and/or Topical Calcineurin Inhibitors in Adult Participants With Moderate-to-severe Atopic Dermatitis (AD)
SKiN Centre for Dermatology /ID# 153853
Peterborough, Ontario K9J 5K2
1 vizsgálat
- NCT03047395A Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis ( LIMMITLESS )
SKIN Centre for Dermatology /ID# 169604
Peterborough, Ontario K9J 5K2
1 vizsgálat
- NCT03675308A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy
SKIN Centre for Dermatology /ID# 200331
Peterborough, Ontario K9J 5K2
1 vizsgálat
- NCT03568318A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis
SKiN Centre for Dermatology /ID# 246291
Peterborough, Ontario K9J 5K2
1 vizsgálat
- NCT05394792An Observational Study of Upadacitinib to Assess Change in Disease Activity in Canadian Adult Participants With Moderate-to-Severe Atopic Dermatitis Who Are Inadequate Responders To or Discontinuing Dupilumab
SKiN Centre for Dermatology /ID# 246702
Peterborough, Ontario K9J 5K2
1 vizsgálat
- NCT05507580A Study to Assess Treat-to-Target and Dosing Flexibility of Oral Upadacitinib Tablets in Adult Participants With Moderate to Severe Atopic Dermatitis
SKiN Centre for Dermatology /ID# 251853
Peterborough, Ontario K9J 5K2
1 vizsgálat
- NCT05601882A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis
SKiN Centre for Dermatology /ID# 255882
Peterborough, Ontario K9J 5K2
1 vizsgálat
- NCT05959070An Observational Study to Validate the Cumulative Life Course Impairment (CLCI) Instrument (DermCLCI-p) in Adult Participants With Moderate to Severe Chronic Plaque Psoriasis (PsO)
SKiN Centre for Dermatology /ID# 258813
Peterborough, Ontario K9J 5K2
1 vizsgálat
- NCT06012240A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata
SKiN Centre for Dermatology /ID# 277594
Peterborough, Ontario K9J 5K2
1 vizsgálat
- NCT07039110Study to Assess Change in Quality of Life of Risankizumab Treatment in Adult Participants With Moderate-to-Severe Plaque Psoriasis
  Contact: Julieta Gonzalez Blanco
SKiN Centre for Dermatology - Peterborough - Probity - PPDS
Peterborough, Ontario K9J 1Z2
1 vizsgálat
- NCT06108544A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period
SKiN Centre for Dermatology (Site 0103)
Peterborough, Ontario K9J 5K2
1 vizsgálat
- NCT06956235Study to Evaluate Tulisokibart for Hidradenitis Suppurativa (MK-7240-012)

Betegségek

Betegségek, amelyekről az intézmény publikál vagy amelyekre vizsgálatot futtat.

Atópiás dermatitisz (ekcéma)34 munka · 12 vizsgálat
Hidradenitis suppurativa6 munka · 4 vizsgálat

Intézményadatok: ROR 005wzfh51 (CC0-1.0)Frissítve: 2026. nov. 12.

Hibát jelzek